SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Shares of MLTX are trending amid a steep decline following mixed results from a Phase 3 trial, leading to significant community discussion around potential short covering and whether the market has overreacted. Some investors are speculating about a possible acquisition by Merck, while others are assessing the company's cash reserves and future prospects. The conversation highlights the volatile nature of biotech stocks and the high-risk, high-reward potential in the sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it reached new all-time highs, driven by optimism around its prediction markets business and expansion into new fintech services. Community members are actively discussing the stock's potential to continue its impressive run, while some caution against overvaluation and a possible pullback. Bullish sentiment is fueled by strong financials and the stock's inclusion in the S&P 500.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

APDN is trending following news of a $58M private placement to initiate a BNB-focused digital asset strategy, with plans to change its ticker to BNBX; the stock experienced multiple trading halts as a result. The community is discussing the potential for a significant price increase, with some drawing comparisons to other low-float runners and noting Scaramucci's involvement as an advisor. This activity occurs amid broader speculation about the company's strategic shift towards digital assets.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors eagerly anticipate the release of its Preliminary Feasibility Study (PFS), with some speculating its imminent arrival could trigger a significant price surge. Bullish sentiment is fueled by increasing volume, government backing, and potential short squeezes, while community members express excitement about the company's long-term prospects in the lithium and battery recycling sectors.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to an ex-FDA employee's LinkedIn post questioning the safety and efficacy of their drug Lupkynis, sparking concerns about potential market manipulation. The community is debating the validity of the claims, the company's response, and possible legal action. Some investors believe this is a strategic move to lower the price before a buyout, while others worry about the drug's reputation and future sales.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is gaining traction as an AI-themed memecoin associated with Elon Musk's Grok AI, with the community rallying behind its potential. Some are pointing to a tight float and potential catalyst related to NXXT, while others highlight the strong community and growing number of holders. It is also being mentioned in the context of other trending coins like $UPDOG.X and $RAGE.X.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a crypto focused on community, freedom, and culture, with some suggesting potential links to broader cannabis industry developments. Community members are actively discussing its vision for growth and its potential as a culture coin. Some users are also discussing where to purchase the coin and celebrating its trending status.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending as traders discuss its recent price surge and potential for further gains, with the community focusing on breaking the $12 resistance level. Some speculate about a short squeeze due to the stock's low float and high trading volume. Others believe the stock is benefitting from funds rotating into policy winning names.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investors debate whether its recent dip presents a buying opportunity or signals deeper concerns about growth and valuation, especially when compared to competitors like Chipotle. Community discussions revolve around the stock's support levels and potential for a rebound, with some pointing to the upcoming Chicken Shawarma menu addition as a catalyst. Despite concerns about the consumer environment and past downgrades, the company's expansion plans and debt-free balance sheet remain key talking points.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending as the community discusses its momentum and potential catalysts, particularly around its NXXT project and the anticipation of future news. Community members are actively watching for breakouts and accumulation patterns, while also considering the possibility of a future offering. Positive trial results and analyst buy ratings appear to be contributing to the current interest in the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Equity

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 


Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during Tirzepatide-induced weight loss in a mid-stage study.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-positive-phase-2-embraze-trial-results">trial</a> demonstrated that 30% of the total weight loss with Tirzepatide alone was due to lean mass loss. Tirzepatide is the active ingredient in Eli Lilly's weight loss therapy Zepbound.Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.Reduction in body weight, however, was marginally higher in patients who received Tirzepatide alone.No subjects experienced serious adverse events or discontinuations considered to be related to apitegromab treatment, and there were no deaths, the company added.Akshay Vaishnaw, President of R&amp;D, Scholar Rock, said that while therapies like Tirzepatide have been an effective innovation for people with obesity, they result in substantial loss of lean muscle mass for patients, leading to unwanted health risks.Vaishnaw added that the company is focused on preparing for the launch of Apitegromab and, following its potential approval for spinal muscular atrophy, looks forward to studying it in a range of neuromuscular diseases with high unmet needs.Approval for Apitegromab in spinal muscular atrophy is expected by late September.Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% of Semaglutide-induced weight loss was due to loss of lean mass. However, combining Semaglutide, the active ingredient in Novo Nordisk’s weight loss drug Wegovy, with Regeneron’s Trevogrumab with or without Garetosmab helped preserve lean mass while increasing loss of fat mass, the company said.On Stocktwits, retail sentiment around Scholar Rock jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_1_49_41_PM_png_73aabfb93c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, noted that the lack of increased weight loss with the combination compared to Tirzepatide alone is bearish.<stembedurl>https://stocktwits.com/BioLong123/message/618251994</stembedurl><a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> is down by 18% this year but up by over 320% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-circle-pop-as-stablecoin-legislation-clears-senate/chlsfGnRR2K">Coinbase, Circle Pop As Stablecoin Legislation Clears Senate – But These Two Stocks Took A Hit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential.Jefferies thinks big pharma companies are "still on the hunt" for deals as Pfizer (PFE), Biogen (BIIB), Merck (MRK), Eli Lilly (LLY), Gilead (GILD), and others have publicly discussed active business development to "fill voids."Jefferies named South San Francisco-based Akero among the names it believes hold promise, alongside Scholar Rock (SRRK).The firm noted that Akero has potential sales of $2 billion to $3 billion and "clean and strong" Phase II data of its lead product candidate, Efruxifermin, in patients with non-alcoholic Steatohepatitis.As for Scholar Rock (SRRK), Jefferies deems it a promising target with likely approval for its investigational treatment Apitegromab in spinal muscular atrophy by late September.The company’s upcoming mid-stage trial data of Apitegromab in obesity "could be a clearing event" that could help simplify the stock's valuation, it added.On Stocktwits, retail sentiment around Akero stayed within ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:625/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_36_24_PM_png_6b185bcea0.webp" alt="AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="625" height="66"><figcaption>AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, all 11 analysts covering AKRO rate it a ‘Buy’ or higher. The stock has an average price target of $76.30.Meanwhile, retail sentiment around SRRK stayed ‘bearish’ over the last 24 hours while message volume took a dip from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:633/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_37_19_PM_png_cb246dfd4a.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="633" height="65"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> All of the 10 analysts covering SRRK also rate it ‘Buy’ or higher, with an average price target of $49.67.While <a href="https://stocktwits.com/symbol/AKRO">AKRO</a> has nearly doubled its value this year, <a href="https://stocktwits.com/symbol/SRRK">SRRK</a> is down by over 25%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/merck-gets-fda-approval-for-keytruda-in-more-head-and-neck-cancer-patients/chliQJzRRbZ">Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mergers and Acquisitions message in neon lights. (Image Courtesy: Getty Images)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased

Jefferies thinks big pharma companies are "still on the hunt" for deals. 

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases...

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious...

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.84	--	--	N/A
Q2 '25	-$0.66	-$0.98	-47.42%	MISSED
Q1 '25	-$0.66	-$0.67	-1.40%	MISSED
Q4 '24	-$0.60	-$0.62	-3.12%	MISSED
Q3 '24	-$0.58	-$0.66	-13.77%	MISSED

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SRRK News

SRRK Scholar Rock Holding Corp